TY - JOUR
T1 - Appraisal of methods for the study of chemotherapy of cancer in man
T2 - Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
AU - Zubrod, Charles G.
AU - Schneiderman, Marvin
AU - Frei, Emil
AU - Brindley, Clyde
AU - Lennard Gold, G.
AU - Shnider, Bruce
AU - Oviedo, Raul
AU - Gorman, John
AU - Jones, Ralph
AU - Jonsson, Ulfar
AU - Colsky, Jack
AU - Chalmers, Thomas
AU - Ferguson, Bruce
AU - Dederick, Margarida
AU - Holland, James
AU - Selawry, Oleg
AU - Regelson, William
AU - Lasagna, Louis
AU - Owens, Albert H.
PY - 1960/1
Y1 - 1960/1
N2 - Suggestions are made for the conduct of chemotherapy trials in patients with cancer. Application of the principles involved are illustrated in a comparative study of triethylene thiophosphoramide and nitrogen mustard in cancer of the lung and breast, melanoma, and Hodgkin's disease. Neither drug was appreciably effective in cancer of the lung which had previously been irradiated or in melanoma. In cancer of the lung not previously irradiated and in cancer of the breast, 30 to 50 per cent reduction in tumor size occurred in 10 to 26 per cent of the patients. In Hodgkin's disease certain factors limit the completeness of the comparison, but it is possible to draw the tentative conclusion that thio-TEPA was less active than HN2 (in the doses used) in inducing remissions. The advantages and disadvantages of this type of trial are discussed and several suggestions are made for improved experimental design.
AB - Suggestions are made for the conduct of chemotherapy trials in patients with cancer. Application of the principles involved are illustrated in a comparative study of triethylene thiophosphoramide and nitrogen mustard in cancer of the lung and breast, melanoma, and Hodgkin's disease. Neither drug was appreciably effective in cancer of the lung which had previously been irradiated or in melanoma. In cancer of the lung not previously irradiated and in cancer of the breast, 30 to 50 per cent reduction in tumor size occurred in 10 to 26 per cent of the patients. In Hodgkin's disease certain factors limit the completeness of the comparison, but it is possible to draw the tentative conclusion that thio-TEPA was less active than HN2 (in the doses used) in inducing remissions. The advantages and disadvantages of this type of trial are discussed and several suggestions are made for improved experimental design.
UR - http://www.scopus.com/inward/record.url?scp=20644459413&partnerID=8YFLogxK
U2 - 10.1016/0021-9681(60)90137-5
DO - 10.1016/0021-9681(60)90137-5
M3 - Article
AN - SCOPUS:20644459413
SN - 0021-9681
VL - 11
SP - 7
EP - 33
JO - Journal of Chronic Diseases
JF - Journal of Chronic Diseases
IS - 1
ER -